Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Cai, Haiqing ^a   Lin, Lijun ^b   Cai, Haikang ^c   Tang, Mingjie ^d   Wang, Zhigang ^a  

^a SHANGHAI CHILDREN S MEDICAL CENTER   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Xuhui Central Hospital   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

miR 210; Overall survival; Pediatric osteosarcoma; Prognosis; Progression free survival

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA 210; MICRORNA; MIRN210 MICRORNA, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; BONE TISSUE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR BIOPSY; UPREGULATION; BIOSYNTHESIS; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; OSTEOSARCOMA; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 84873970191     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0499-6     Document Type: Article

References (24)

1. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011;2011:959248.
2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3-13.
3. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis. 2011;28:493-503.
4. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705-18.
5. Osman A. MicroRNAs in health and disease-basic science and clinical applications. Clin Lab. 2012;58:393-402.
6. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13:e249-58.
7. Subramanian S, Kartha RV. MicroRNA-mediated gene regulations in human sarcomas. Cell Mol Life Sci. 2012;69:3571-85.
8. Lulla RR, Costa FF, Bischof JM, Chou PM. de F Bonaldo M, Vanin EF, Soares MB. Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma. 2011;2011:732690.
9. Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R, Banfi C, Stubbs A, Calin GA, Ivan M, Capogrossi MC, Martelli F. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009;284:35134-43.
10. Mizuno Y, Tokuzawa Y, Ninomiya Y, Yagi K, Yatsuka-Kanesaki Y, Suda T, Fukuda T, Katagiri T, Kondoh Y, Amemiya T, Tashiro H, Okazaki Y. miR-210 promotes osteoblastic differentiation through inhibition of AcvR1b. FEBS Lett. 2009;583:2263-8.
11. Huvos AG. Osteosarcoma in adolescents and young adults: new developments and controversies. Commentary on pathology. Cancer Treat Res. 1993;62:375-7.
12. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
13. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3:e47.
14. Hong L, Han Y, Zhang H, Zhao Q, Qiao Y. miR-210: a therapeutic target in cancer. Expert Opin Ther Targets. 2013;17:21-8.
15. He J, Wu J, Xu N, Xie W, Li M, Li J, Jiang Y, Yang BB, Zhang Y. MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes. Nucleic Acids Res. 2012 In press.
16. Merlo A, de Quiros SB, Secades P, Zambrano I, Balbín M, Astudillo A, Scola B, Arístegui M, Suarez C, Chiara MD. Identification of a Signaling Axis HIF-1α/MicroRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas. J Clin Endocrinol Metab. 2012;97:E2194-200.
17. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM, Polymeneas G, Voros D. Expression of MicroRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas. 2012 In press.
18. Hong L, Yang J, Han Y, Lu Q, Cao J, Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene. 2012;507:135-8.
19. Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microrna expression in lung cancer. Int J Cancer. 2012 In press.
20. Wotschofsky Z, Busch J, Jung M, Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller K, Kristiansen G, Erbersdobler A, Jung K. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta. 2012 In press.
21. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res. 2009;2:807-13.
22. Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M, Sotiriou C. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS ONE. 2011;6:e20980.
23. Greither T, Würl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschläger C, Holzhausen HJ, Wach S, Eckert AW, Taubert H. Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. Int J Cancer. 2012;130:1230-5.
24. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J, Harris AL. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer. 2010;116:2148-58.